Driving the hemophilia tolerance CAR

Abstract

T-cell immunotherapy against cancer, using chimeric antigen receptors (CARs) to specifically target tumor antigens without major histocompatibility complex (MHC) restriction, is widely viewed as one of the major scientific breakthroughs of recent years.1 In this issue of Blood, Yoon et al demonstrate that this approach can be adapted to redirect specificity of regulatory T cells (Tregs) to coagulation factor VIII (FVIII), thereby suppressing antibody (“inhibitor”) development in replacement therapy for hemophilia A.